Nomura Holdings Inc. Invests $519,000 in Haemonetics Co. (NYSE:HAE)

Nomura Holdings Inc. purchased a new position in Haemonetics Co. (NYSE:HAE - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 6,652 shares of the medical instruments supplier's stock, valued at approximately $519,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics during the 4th quarter valued at $25,000. Covestor Ltd boosted its stake in shares of Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after buying an additional 439 shares during the period. Whittier Trust Co. acquired a new stake in shares of Haemonetics during the 4th quarter valued at $62,000. Parkside Financial Bank & Trust boosted its stake in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after buying an additional 240 shares during the period. Finally, AlphaQuest LLC boosted its stake in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after buying an additional 1,826 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HAE. JMP Securities reissued a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a research note on Tuesday, May 20th. Bank of America downgraded shares of Haemonetics from a "neutral" rating to an "underperform" rating and cut their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. Needham & Company LLC cut their price target on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Barrington Research cut their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Finally, Wall Street Zen downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $97.89.

Haemonetics Price Performance

Shares of Haemonetics stock traded up $1.86 during trading on Tuesday, hitting $67.92. 532,531 shares of the company's stock traded hands, compared to its average volume of 682,996. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The firm's fifty day moving average price is $63.22 and its 200 day moving average price is $70.72. Haemonetics Co. has a twelve month low of $55.30 and a twelve month high of $94.99. The company has a market cap of $3.26 billion, a PE ratio of 26.74, a PEG ratio of 1.11 and a beta of 0.32.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The company had revenue of $330.60 million during the quarter, compared to analysts' expectations of $329.38 million. During the same quarter in the previous year, the company posted $0.90 earnings per share. Haemonetics's quarterly revenue was down 3.5% compared to the same quarter last year. Analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.